Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 15/20 | 0.91 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.91 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.91 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.91 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.91 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.91 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.91 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.91 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.91 |
| ▸ | PRKDC | P78527 | 1/20 | 0.91 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.91 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.91 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.91 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.91 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.91 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6878217 | 0.97 | MTOR (0.87) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| Torin1 SCHEMBL29357575 | 0.95 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| Torin1 SCHEMBL7919574 | 0.95 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| Torin1 SCHEMBL29350222 | 0.95 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| Torin1 SCHEMBL29499920 | 0.95 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6877194 | 0.93 | MTOR (0.84) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6874967 | 0.93 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6877975 | 0.92 | MTOR (0.93) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL7919237 | 0.92 | MTOR (1.00) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG | |
| SCHEMBL6877181 | 0.90 | MTOR (0.86) | MTORPIK3C2APIK3C2BPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180185374-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2018-07-05 | — | — | US | disclosed |
| US-20180185374-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2018-07-05 | — | — | US | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889706-B2 | Soluble mTOR complexes and modulators thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140018354-A9 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | KADMON CORPORATION, LLC | 2014-01-16 | — | — | US | disclosed |
| US-20140018354-A9 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | KADMON CORPORATION, LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-8394818-B2 | Soluble mTOR complexes and modulators thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | MOORMAN NATHANIEL (US) | 2012-07-26 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011011716-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010044885-A2 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190676-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | EIF2AK2, MTOR, EIF4EBP1 | MTOR 2/4885PIK3C2A 271/4885PIK3C2B 329/4885 |
| US-20130072485-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3C2A 18/4885PIK3C2B 16/4885 |
| US-20180185374-A1 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | EIF2AK2, MTOR, EIF4EBP1 | MTOR 2/4885PIK3C2A 271/4885PIK3C2B 329/4885 |
| US-20140018354-A9 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS | EIF2AK2, MTOR, EIF4EBP1 | MTOR 2/4885PIK3C2A 271/4885PIK3C2B 329/4885 |
| US-20110288091-A1 | SOLUBLE MTOR COMPLEXES AND MODULATORS THEREOF | MTOR, RICTOR, RPTOR | MTOR 1/4885PIK3C2A 18/4885PIK3C2B 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.